Tecan Group AG · SIX:TECN
Tecan — CS Swiss EQ Mid Cap Conference 2017
24 slides from Tecan's conference presentation, Nov 17, 2017
Slide 1: CS Swiss EQ Mid Cap Conference 2017
Tecan Group CS Swiss EQ Mid Cap Conference 2017 DR. DAVID MARTYR, CEO NOVEMBER 17, 2017 ZURICH
Slide 2: Introduction
i) & eo) > O win. xe) (e) Some —
Slide 3: Tecan's Vision Statement
Tecan’s Vision Statement Our vision is to empower every laboratory, every day, around the world with Tecan technology, products and support. We will help to shape the future of automated workflows in life sciences and clinical diagnostics through unrivaled expertise, products and customer support. 3
Slide 4: Tecan in the Center of a Dynamic Environment
Tecan in the Center of a Dynamic Environment Genomics LCMS Molecular Biobanking Diagnostics Synthetic Immuno Biology Diagnostics Cell Biology Protein Next-Gen Histology Sciences Sequencing Pathology Applied Markets CRISPR …and Liquid many more Biopsies 4
Slide 5: Introducing Tecan
Introducing Tecan • Pioneer and global leader in laboratory automation since over 35 years • Our solutions accelerate, automate and enhance the processes in state-of-the-art diagnostics and life sciences labs • Offering solutions in select application areas: immunoassays for specialty diagnostics an
Slide 6: Tecan's Products, Business Structure and Markets
Tecan’s Products, Business Structure and Markets LIFE SCIENCES BUSINESS PARTNERINGBUSINESS PARTNERING BUSINESS • Focused on all end-user activities • Focused on all OEM activities • Products marketed under the Tecan brand • Products sold by partners under their own through own sales & service organi
Slide 7: Revenue Profile Provides a Solid Basis
Revenue Profile Provides a Solid Basis STRONG DRIVERS ACQUISITIONS ADDING GROWING DIRECT PRESENCE IN DIAGNOSTICS NEW SOURCES IN EMERGING MARKETS OF RECURRING REVENUES Customer Segments Products Geographies 5% 3% 12% 15% ≈ 40% ≈ 60% 21% 62% 43% 39% Research and Applied Instruments Diagnostics Europe
Slide 8: Strategy and Growth Drivers
Strategy and com Growth Drivers = __,. — L . l l I I I I l I TECAN
Slide 9: Basis for Corporate Strategy: Market Structure
Basis for Corporate Strategy: Market Structure LIFE SCIENCE RESEARCH IN-VITRO DIAGNOSTICS STRATEGIC PILLARS CAGR +3-5% +3-5% 1 Scale & 40-50 BN USD 40-50 BN USD capability Reagents & Consumables 3 Reagents & Consumables 2 Build additional pillars and complete portfolio 2 Instruments 3 Offer Instrume
Slide 10: New Platforms in Two Main Instrument Segments
New Platforms in Two Main Instrument Segments LIFE SCIENCES BUSINESS STRONG MARKET UPTAKE AND ORDER MOMENTUM FLUENT ®* NEXT GENERATION LIQUID SPARK ®* NEXT GENERATION HANDLING PLATFORM FAMILY READER PLATFORM Setting new standards for simplicity, Greater flexibility, increased speed productivity and
Slide 11: Growing Solutions Offering in Select Applications
Growing Solutions Offering in Select Applications LIFE SCIENCES BUSINESS LEVERAGING TECAN’S GLOBAL PRESENCE AND CUSTOMER BASE IMMUNOASSAYS FOR SPECIALTY SAMPLE PREPARATION SOLUTIONS DIAGNOSTICS FOR MASS SPECTROMETRY Building on Tecan’s long tradition in Leveraging Tecan’s leading position in mass im
Slide 12: Partner of Choice to the IVD Industry
Partner of Choice to the IVD Industry PARTNERING BUSINESS 25+ ACTIVE INSTRUMENT ACCOUNTS, MARKET LEADER IN COMPONENTS DAKO OMNIS ORTHO VISION™ ANALYZER FOR FOR AGILENT TECHNOLOGIES ORTHO CLINICAL DIAGNOSTICS Advanced staining platform for tissue-based Next generation diagnostics instrument for cance
Slide 13: Additional Instruments Ramping Up in 2017
Additional Instruments Ramping Up in 2017 PARTNERING BUSINESS PROVIDING BASIS FOR CONTINUED GROWTH Sgx ClarityTM System Inova QUANTA Lyser® VIRCLIA® PLUS 3000 High sensitivity next gen immunodiagnostics IFA/ELISA for autoimmunity Chemoluminescence IA for infectious diseases Natch S MultiMACS®X Top 1
Slide 14: New Instrument Developments
New Instrument Developments PARTNERING BUSINESS MULTIPLE NEW DEVELOPMENTS IN PROCESS AND BROAD PIPELINE NEW PLATFORM FOR DIASORIN NEW PLATFORM FOR SYSMEX Nucleic Acid extraction for MDx Sample preparation for flow cytometry Prototype instrument • Use of Tecan’s Fluent® Laboratory Automation • Develo
Slide 15: Acquisitions, Key Element of Corporate Strategy
Acquisitions, Key Element of Corporate Strategy ACQUISITIONS ANNOUNCED TO DATE 3 August 2016: Acquisition of SPEware 2 • Leading provider for mass spectrometry sample preparation solutions • Further expanding Tecan’s dedicated solutions offering • Over 70% of revenues from smart consumables; also of
Slide 16: Financials, Outlook and Summary
Financials, Outlook and Summary
Slide 17: Financial Performance H1 2017
Financial Performance H1 2017 • Significant increase in order entry; +16.7% and +12.5% organic • Substantial sales growth of +18.2% in Life Sciences Business (+9.5% organic) • Strong growth in components business, services and consumables as part of Partnering Business; double-digit increase in orde
Slide 18: Outlook for 2017 Confirmed
Outlook for 2017 Confirmed SALES DEVELOPMENT OPERATING PROFIT (EBITDA) Sales to increase by 550 more than 6% in LC 110.0 EBITDA margin to 525 CHF (mio) 506.2 expand to over 18%1 500 100.0 89.0 CHF (mio) 475 90.0 440.3 83.4 450 80.0 425 399.5 67.5 391.1 388.3 70.0 63.0 65.1 400 375 60.0 350 50.0 2012
Slide 19: Advancing Tecan
Advancing Tecan OUTGROWING MARKET ORGANICALLY • Life Sciences Business with new and leading product portfolio and improved organization • Growing solutions offering in select applications • Partnering Business with multiple platforms in ramp up phase and broad pipeline INCREASING PROFITABILITY • Com
Slide 20: FY 2016 Key Figures
FY 2016 Key Figures 2015 2016 Δ IN % Sales (in CHF mio) 440.3 506.2 +15.0% Sales in local currencies (in CHF mio) 446.1 506.2 +13.5% Gross Profit (in CHF mio) 215.5 239.4 +11.1% in % of sales 48.9% 47.3% R&D (in CHF mio) 39.9 47.1 +18.1% in % of sales 9.1% 9.3% EBIT (in CHF mio) 66.9 68.1 +1.8% in %
Slide 21: H1 2017 Key Figures
H1 2017 Key Figures 2016 2017 Δ IN % Order Entry (in CHF mio) 250.6 291.2 +16.2% Sales (in CHF mio) 235.3 253.3 +7.7% Sales in local currencies (in CHF mio) 234.5 253.3 +8.0% Gross Profit (in CHF mio) 112.3 119.9 +6.7% in % of sales 47.7% 47.3% R&D (in CHF mio) 22.9 23.5 +2.8% in % of sales 9.7% 9.3
Slide 22: Q&A
Q&A IR IPAD APP CONTACT News, financial reports, Martin Braendle presentations, Vice President, Communications & IR videos and more Phone: +41 (0) 44 922 84 30 investor@tecan.com NEXT EVENT 2018 www.tecan.com March 14: Full Year Results 2017 April 17: Annual Shareholder Meeting 22
Slide 23: > ry y
> ry y aT) with FFF j A ican | f 8 OF gf a i
Slide 24: Tecan – Who we are
Tecan – Who we are Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the lif